NCT02625714

Safety/Tolerability and Pharmacokinetic Study of SID142

A Randomized, Open-label, Oral Multiple Dosing, Two-way Crossover Clinical Trial to Evaluate the Safety/Tolerability and Pharmacokinetic Profiles of SID142 in Healthy Volunteers

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 41 (actual)
• Sponsor: SK Chemicals Co., Ltd. · Industry
• Sex: All
• Age: 19 Years – 45 Years
• Healthy volunteers: Accepted

Summary

A randomized, open-label, oral multiple dosing, two-part, two-way crossover clinical trial to evaluate the safety/tolerability and pharmacokinetic profiles of SID142 in healthy volunteers

Conditions

• Arterial Occlusive Diseases

Interventions

Type	Name	Description
DRUG	Renexin®	Cilostazol 100mg/ginko biloba leaf extract 80mg, Immediate release, bid
DRUG	SID142	Cilostazol 200mg/ginko biloba leaf extract 160mg, Controlled release, qd

Timeline

• Start date: 2015-06-01
• Primary completion: 2015-07-01
• Completion: 2015-07-01
• First posted: 2015-12-09
• Last updated: 2015-12-14